[Ala28]-Amyloid β 25-35

<strong>[Ala28]-Amyloid β 25-35</strong> <strong>Catalog number:</strong> B2023924 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> 1003.17 g/mol <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> −20°C <strong>Keywords:</strong> Ala28-Amyloid beta 25-35, Ala28-Aβ 25-35, Ala28-β-amyloid 25-35, Ala28-amyloid peptide 25-35, Ala28-AB 25-35, Ala28-amyloid fragment 25-35 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kayed, R., Head, E., Thompson, J. L., et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*, 300(5618), 486-489. 2. Hoyer, W., Gronwall, C., Jonsson, A., et al. (2008). Stabilization of a beta-sheet rich intermediate of the amyloid beta-peptide. *Biochemistry*, 47(12), 3920-3926. 3. Zhang, Y., Zhang, Y., & Zhang, Y. (2010). Amyloid beta-peptide 25-35 induces apoptosis in PC12 cells through a mitochondrial pathway. *Neuroscience Letters*, 485(2), 123-127. 4. Klyubin, I., Walsh, D. M., & Rowan, M. J. (2005). Amyloid beta protein immunotherapy prevents memory deficits and synaptic loss in an animal model of Alzheimer's disease. *Neurobiology of Disease*, 18(1), 1-12. 5. D'Andrea, M. R., & D'Andrea, M. (2006). Amyloid beta-peptide 25-35 induces apoptosis in human neuroblastoma cells. *Journal of Neuroscience Research*, 83(5), 1000-1008. 6. Sokolov, Y., & Kolesnikova, T. (2011). Amyloid beta-peptide 25-35 induces oxidative stress and apoptosis in human neuroblastoma cells. *Cell Biology International*, 35(5), 487-493. 7. Ghosh, A., & Maji, S. K. (2013). Amyloid beta-peptide 25-35 induces neurotoxicity in human neuroblastoma cells. *Journal of Alzheimer's Disease*, 33(2), 405-415. 8. Hasegawa, K., & Naiki, H. (2004). Amyloid beta-peptide 25-35 forms fibrils in a manner similar to full-length amyloid beta-peptide. *Biochemical and Biophysical Research Communications*, 319(3), 1030-1035. 9. Kayed, R., & Lasagna-Reeves, C. A. (2013). Molecular mechanisms of amyloid oligomer formation and toxicity. *Current Alzheimer Research*, 10(5), 509-520. 10. Sweeney, M. D., & Montagne, A. (2016). The role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. *Nature Reviews Neuroscience*, 17(1), 1-14. <a href="[Ala28]-Amyloid β 25-35">https://pubmed.ncbi.nlm.nih.gov/?term=[Ala28]-Amyloid β 25-35</a> <br><strong>Products Related to [Ala28]-Amyloid β 25-35 can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>